Melanoma Biomarker Symposium

18 September 2019

Woodward Centre, Pelham St, Carlton

11 am – 5 pm (Registration open from 10:30 am)

PROVISIONAL PROGRAM

Time	Topic	Suggested Speaker
11:00	Welcome & Intro Consumer Perspective	*David Gyorki* *VCCC Research & Education Lead* *Alison Button-Sloan* *Chair Consumer Committee Melanoma Research Victoria*
Session 1 Novel Biomarkers – Chair: Andreas Behren, ONJCRI, VIC		
11:10	**Keynote lecture 1**: Innovation in risk-stratification (including genomic testing)	*Alex Meves, MD* *Mayo Clinic, Rochester MN, USA*
11:40	Questions and Discussion	
11:50	Autoantibodies as biomarkers	*Jessica Duarte* *ONJCRI, VIC*
12:05	MicroRNA biomarkers: Assessment of precision melanoma diagnostics	*Mitchell Stark* *University of Queensland, QLD*
12:20	Noncoding mutations in the transition from naevus to melanoma	*Andrew Colebatch* *Royal Prince Alfred Hospital and Melanoma Institute Australia, NSW*
12:35	A natural killer cell gene signature as a prognostic biomarker	*Joseph Cursons* *Walter & Eliza Hall Institute and oNKo-innate, VIC*
12:50	Panel discussion – Moderator Andreas Behren	
1:05 – 1:45	*Lunch*	

Time	Topic	Suggested Speaker
Session 2: Biomarker platforms – Chair: Victoria Mar, Victorian Melanoma Service, VIC		
1:45	**Keynote lecture 2**: How do we take novel biomarkers from publication to the clinic?	*Maarten IJzerman* *University of Melbourne, VIC*
2:15	Questions & Discussion	
2:25	Bioinformatic models for biomarker research	*Tony Papenfuss* *WEHI/Peter Mac, VIC*
2:40	Predicting which early stage melanomas will do badly	*Victoria Mar* *Victorian Melanoma Service* *Alfred Health, VIC*
2:55	PET imaging as a predictor of immunotherapy response	*Amir Iravani* *Peter Mac, VIC*
3:10	ctDNA as a prognostic & predictive biomarker	*Alex Dobrovic* *ONJCRI, VIC*
3:25 – 3:45	*Tea break*	
Session 3: Predictive biomarkers – Chair: George Au Yeung, Peter MacCallum Cancer Centre, VIC		
3:45	Predicting response to immunotherapy: Tumour factors including TML, PD-L1 status	*Oliver Klein* *ONJCRI, VIC*
4:00	Predicting response to immunotherapy: The exceptional responder – what can we learn?	*Inês Silva* *Melanoma Institute Australia, NSW*
4:15	Assessing pathology response to neoadjuvant therapy	*Louise Jackett* *Austin Health, VIC*
4:30	Panel Discussion – Moderator Grant McArthur	
5:00	*Close*	
	Refreshments	